TD Asset Management Inc Buys 35,272 Shares of CG Oncology, Inc. $CGON

TD Asset Management Inc lifted its stake in CG Oncology, Inc. (NASDAQ:CGON) by 23.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 186,448 shares of the company’s stock after acquiring an additional 35,272 shares during the period. TD Asset Management Inc’s holdings in CG Oncology were worth $7,741,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. AQR Capital Management LLC purchased a new stake in shares of CG Oncology during the first quarter valued at $475,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in CG Oncology by 18.1% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 35,522 shares of the company’s stock worth $876,000 after buying an additional 5,442 shares during the last quarter. Millennium Management LLC boosted its holdings in shares of CG Oncology by 139.4% in the 1st quarter. Millennium Management LLC now owns 596,056 shares of the company’s stock valued at $14,597,000 after acquiring an additional 347,055 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in shares of CG Oncology by 42.5% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 179,363 shares of the company’s stock worth $4,393,000 after acquiring an additional 53,461 shares during the period. Finally, Legal & General Group Plc raised its stake in shares of CG Oncology by 12.3% during the 2nd quarter. Legal & General Group Plc now owns 44,354 shares of the company’s stock valued at $1,153,000 after buying an additional 4,847 shares during the last quarter. Hedge funds and other institutional investors own 26.56% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently issued reports on CGON. Truist Financial reissued a “buy” rating and set a $82.00 target price (up from $77.00) on shares of CG Oncology in a research note on Thursday, May 14th. HC Wainwright reiterated a “buy” rating and set a $100.00 price target on shares of CG Oncology in a research report on Monday, May 18th. JPMorgan Chase & Co. raised their price objective on CG Oncology from $91.00 to $96.00 and gave the company an “overweight” rating in a report on Monday, May 11th. Royal Bank Of Canada boosted their price objective on CG Oncology from $79.00 to $81.00 and gave the company an “outperform” rating in a research report on Monday, May 11th. Finally, Wedbush lifted their target price on shares of CG Oncology from $77.00 to $80.00 and gave the company an “outperform” rating in a research report on Monday, May 11th. Eleven equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, CG Oncology presently has an average rating of “Moderate Buy” and an average target price of $81.73.

Insider Buying and Selling

In other news, Director Leonard E. Post sold 1,000 shares of the company’s stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $54.50, for a total value of $54,500.00. Following the transaction, the director directly owned 1,000 shares in the company, valued at approximately $54,500. This represents a 50.00% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director James Mulay sold 15,600 shares of CG Oncology stock in a transaction that occurred on Friday, April 17th. The shares were sold at an average price of $73.01, for a total transaction of $1,138,956.00. Following the completion of the sale, the director owned 15,600 shares of the company’s stock, valued at $1,138,956. This trade represents a 50.00% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 18,564 shares of company stock worth $1,318,170 over the last three months. Insiders own 4.80% of the company’s stock.

CG Oncology Stock Performance

Shares of CG Oncology stock opened at $56.67 on Wednesday. CG Oncology, Inc. has a fifty-two week low of $23.65 and a fifty-two week high of $75.50. The stock has a 50 day moving average of $65.57 and a 200 day moving average of $56.31. The firm has a market capitalization of $5.00 billion, a price-to-earnings ratio of -24.32 and a beta of 0.31.

CG Oncology (NASDAQ:CGON) last issued its quarterly earnings data on Friday, May 8th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.13). The company had revenue of $1.08 million during the quarter, compared to analysts’ expectations of $0.45 million. Analysts forecast that CG Oncology, Inc. will post -2.89 EPS for the current year.

CG Oncology Profile

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.